Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment‐naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 7, 2015-10 ,pp. : 829-844

John Wiley & Sons Inc

Access to resources Recommend Favorite

Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co‐infected patients

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 1, 2015-01 ,pp. : 25-36

John Wiley & Sons Inc

Access to resources Recommend Favorite

Characteristics and Outcomes of HCV Genotype-1-Infected Patients Treated with Peginterferon and Ribavirin Combination Therapy with Discordant HCV Responses 4 and 12 Weeks after Starting Therapy

By  

Intervirology, Vol. 57, Iss. 5, 2014-06 ,pp. : 289-296

Karger

Access to resources Recommend Favorite

Impact of the peginterferon‐α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV‐co‐infected patients with the unfavourable non‐CC IL28B genotypes

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 21, Iss. 3, 2014-03 ,pp. : 178-188

John Wiley & Sons Inc

Access to resources Recommend Favorite

Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon‐based therapy: FUNDAMENTAL, a Phase II trial

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 7, 2015-07 ,pp. : 596-606

John Wiley & Sons Inc

Access to resources Recommend Favorite